|Other Names||Zinc finger protein ubi-d4, Apoptosis response zinc finger protein, BRG1-associated factor 45D, BAF45D, D4, zinc and double PHD fingers family 2, Protein requiem, DPF2, BAF45D, REQ, UBID4|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1451a was selected from the N-term region of human DPF2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||BAF45D, REQ, UBID4|
|Function||May be a transcription factor required for the apoptosis response following survival factor withdrawal from myeloid cells. Might also have a role in the development and maturation of lymphoid cells.|
|Cellular Location||Nucleus. Cytoplasm. Note=30% nuclear. 70% cytoplasmic|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DPF2 is a member of the d4 domain family, characterized by a zinc finger-like structural motif. This protein functions as a transcription factor which is necessary for the apoptotic response following deprivation of survival factors. It likely serves a regulatory role in rapid hematopoietic cell growth and turnover. DPF2 gene is considered a causal candidate for multiple endocrine neoplasia type I, an inherited cancer syndrome involving multiple parathyroid, enteropancreatic, and pituitary tumors.
Olsen,J.V.,Cell 127 (3), 635-648 (2006)Beausoleil,S.A.,Proc. Natl. Acad. Sci. U.S.A. 101 (33), 12130-12135 (2004)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.